One-Third of Antimalarial Medicines Sampled in Three African Nations Found to Be Substandard in Large-Scale USP... ( Inadequacies May Contribute t...)

HOME >> MEDICINE >> TECHNOLOGY

One-Third of Antimalarial Medicines Sampled in Three African Nations Found to Be Substandard in Large-Scale USP-WHO Study

Date:2/8/2010

Inadequacies May Contribute to Drug Resistance

ROCKVILLE, Md., Feb. 8 /PRNewswire-USNewswire/ -- The first results from a large-scale study of key antimalarial medicines in ten Sub-Saharan African countries reveal that a high percentage of medicines circulating on national markets are of substandard quality and thus may contribute to the growth of drug-resistant strains of Plasmodium falciparum, the most virulent form of malaria. The findings, released today by the Promoting the Quality of Medicines (PQM) Program, a USAID-funded program implemented by the U.S. Pharmacopeial Convention (USP), are for three countries surveyed in the study -- Madagascar, Senegal and Uganda.

The results are part of the larger Quality of Antimalarials in Sub-Saharan Africa (QAMSA) study, a ten-country collaborative study conducted by the World Health Organization (WHO) and PQM. Within Madagascar, Senegal and Uganda, the study sampled 491 antimalarials, performed basic testing on almost all, and submitted 197 samples to full-scale quality control testing. The focus was on artemisinin-based combination therapy (ACT) products, currently the WHO's recommended form of first-line treatment for uncomplicated malaria, and sulfadoxine-pyrimethamine (SP) products, often used for preventative treatment of malaria during pregnancy. The samples were collected from the public and regulated private sectors in these countries, as well as from informal markets, as many patients obtain their medicines from these sources. Substandard and counterfeit versions of antimalarial medicines are highly problematic throughout Africa,
'/>"/>

SOURCE U.S. Pharmacopeial Convention
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. 92 Medicines and Vaccines now in Development for HIV/AIDS
2. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
3. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
4. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
5. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia
6. Report on 750 New Medicines in Development for Cancer Released in Baton Rouge
7. European Medicines Agency Adopts Positive Opinion for Ranolazine for Treatment of Chronic Angina
8. AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
9. More Than 300 New Medicines Being Developed for Mental Illnesses
10. Report on 300 New Medicines in Development for Heart Disease and Stroke Released in Indianapolis
11. New Report Shows Record Number of Medicines in Development to Treat Leading Causes of Cancer

Post Your Comments:

(Date:5/21/2013)... FREDERICK, Md. , May 21, 2013 /PRNewswire/ ... inexpensive, disposable drug-free consumer electronic devices, announced that ... is presenting today to the FDA,s Medical Advisory ... reclassifying the company,s products for over the counter ... the FDA developed its medical device classification schema," ...

(Date:5/21/2013)... , May 21, 2013 Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...

(Date:5/21/2013)... , May 21, 2013 ... report is available in its catalogue: ... and Reimbursement Scenario for Medical Devices in ... Changing Regulatory ... the US Market ...

Breaking Medicine Technology:BioElectronics Presents FDA Reclassification Panel 2 BioElectronics Presents FDA Reclassification Panel 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6 Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3 Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4

[0] BioElectronics Presents FDA Reclassification Panel [0] Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients [0] Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market

... M. Bergman, Chairman and Chief Executive Officer of ... the largest provider of health care products and ... impact of a world without effective antibiotics before ... leaders of society at the World Economic Forum,s ...

... 2012 Vision-Sciences, Inc. (NASDAQ: VSCI), a leading provider ... disposable EndoSheath® technology, today announced its participation at ... TIME: 2:30 PM EST ... "register/ watch event now" button. This ...

Cached Medicine Technology:Henry Schein's Chairman and CEO Addresses the World Economic Forum 2 Henry Schein's Chairman and CEO Addresses the World Economic Forum 3 Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd 2

Henry Schein's Chairman and CEO Addresses the World Economic Forum Vision-Sciences, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 2nd

(Date:5/21/2013)... have long been known for their health benefits, ... therapies like anti-cancer drugs are delivered to specific ... uncovered how to create nanoparticles using natural lipids ... use them as drug delivery vehicles. UofL scientists ... their team today (May 21, 2013), published their ...

(Date:5/21/2013)... Residents in St. Petersburg, FL have a ... Dr. David Sherberg, DMD, has joined Coast Dental Pasadena, ... provides preventive, restorative and cosmetic dentistry to patients age ... provide a wide variety of services including ... crowns, bridges, dentures, dental implant restorations, veneers, laser therapy, ...

(Date:5/21/2013)... May 21, 2013 Vyopta Incorporated, ... automation applications for video collaboration, today announced the ... index evaluates key performance metrics related to quality, ... immediate, aggregated indicator of the performance of their ... Vyopta vAnalytics™ application, the vRating™ delivers high level ...

(Date:5/21/2013)... TheBeautyPlace.com helps brides to breathe a ... Big Day Kit including all the essentials a glowing ... on their Wedding Day. , TheBeautyPlace.com features Wedding Day ... their Wedding Day. Flowers blooming and warmer weather indicates ... season. From Memorial Day to October, brides to be ...

(Date:5/21/2013)... the sound of galloping hooves behind you, your immediate reaction ... it is actually a zebra approaching. Doctors are trained to ... their practices, and as they rarely or never meet a ... takes many years to reach the right diagnosis. A new ... many cases. , Ole Winther is Associate Professor at ...

Breaking Medicine News(10 mins):Health News:UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery 2 Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 2 Health News:Coast Dental Pasadena Welcomes Dr. David Sherberg 3 Health News:New vRating™ Video and Unified Communications Scoring System Delivers Innovative Approach to Measure Performance and ROI for Collaboration Networks 2 Health News:New vRating™ Video and Unified Communications Scoring System Delivers Innovative Approach to Measure Performance and ROI for Collaboration Networks 3 Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 2 Health News:TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season 3 Health News:New search engine finds rare diagnoses 2 Health News:New search engine finds rare diagnoses 3

[0] UofL scientists uncover how grapefruits provide a secret weapon in medical drug delivery [0] Coast Dental Pasadena Welcomes Dr. David Sherberg [0] New vRating™ Video and Unified Communications Scoring System Delivers Innovative Approach to Measure Performance and ROI for Collaboration Networks [0] TheBeautyPlace.com Previews their Emergency Big Day Kit to Get Brides Ready For this Upcoming Wedding Season [0] New search engine finds rare diagnoses

... May 16 /Xinhua-PRNewswire-FirstCall/ -- BMP,Sunstone Corporation (Nasdaq: BJGP ) ... that the Company,will present at the following conferences:, ... cities in China. David Gao, ... scheduled to present on May 19, 2008, ...

... University of Texas M. D. Anderson Cancer Center have ... shutting down their energy source and hastening cell starvation. ... fellow from the Children,s Cancer Hospital at M. D. ... with mTOR inhibitor, rapamycin, induced more than 90 percent ...

... Available, RADNOR, Pa., May 16 This ... Older Pennsylvanians Month, Feeling Blue,Suicide Prevention Council (SPC) ... a public service announcement. The public service,announcement developed ... awareness,to the public health problem of depression and ...

... Conn., May 16 Tao Formulations announces ... Relief Formula, at the Internal,Medicine 2008 conference ... culmination of years of research to develop ... menopausal symptoms., Company founder and CEO, ...

... 2 Diabetes and High LDL- ... Cholesterol ... ACE/AACE Road Maps, PARSIPPANY, N.J., May 16 Daiichi Sankyo, Inc. (DSI),announced ... combination with metformin- or,sulfonylurea- based therapy, significantly lowers blood glucose (as,measured by A1C) ...

... number of women undergoing mastectomy (total breast removal) for ... years at Mayo Clinic in Rochester. The increase follows ... Researchers say the reasons for this increase are unclear. ... who underwent diagnostic magnetic resonance imaging (MRI) prior to ...

Cached Medicine News:Health News:BMP Sunstone Announces Participation in May Investor Conferences 2 Health News:New drug combination brings 1-2 punch against acute leukemia 2 Health News:Suicide Prevention Group Delivers Much-Needed Message to Pennsylvania's Elderly 2 Health News:Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula 2 Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 2 Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 3 Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 4 Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 5 Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 6 Health News:Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes 7 Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 2 Health News: Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers 3

BMP Sunstone Announces Participation in May Investor Conferences New drug combination brings 1-2 punch against acute leukemia Suicide Prevention Group Delivers Much-Needed Message to Pennsylvania's Elderly Tao Formulations Announces the Official Launch of Tao Harmony - Menopause Relief Formula Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes Mastectomies on the rise and MRI use may explain part of the trend, say Mayo researchers

Designed to insert eye spheres using spring loaded plunger. Polished finish. Overall length: 125 mm, 4.9 inches....

Size: Large. 24.50 mm by 26.00 mm. Clear lucite. Supplied sterile....

... x 80 mm. Storz offers the ... by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...

... 5.0 x 80 mm. Storz offers ... designed by Harvey A. Lincoff, M.D. ... sponge which is non-toxic and non-antigenic. ... to minimize scleral intrusion. These implants ...

Medicine Products:

Carter Sphere Introducer and Holder Symblepharon Ring - Large Grooved Segmental Buckle - 2.3 x 6.4 x 80 mm Cylindrical Sponge Implants - 5.0 x 80 mm